Subgroup analysis revealed that GZMK expression levels were relatively higher in patients with ER-negative breast cancer (Figures S2A–D), PR-negative breast cancer (Figures S2F, G), and HER2-positive breast cancer (Figure S2E). Here, ERBB2 is linked to breast carcinoma.